Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
Blood Cancer Journal|January 30, 2025
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndromeLaetitia Largeaud, Vincent Fregona, Laura A Jamrog, et al.
Cancers|July 3, 2020
Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In VivoNizar Serhan, Pierre-Luc Mouchel, Philippe de Medina, et al.
Cancer Research|May 12, 2025
Modeling the PAX5P80R Mutation Reveals HIF2α Activation as a Common Feature and Therapeutic Target in B-Cell Acute Lymphoblastic LeukemiaManon Bayet, Vincent Fregona, Mathieu Bouttier, et al.
Cancer Medicine|February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapyHarmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Leukemia & Lymphoma|May 31, 2022
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry studyNoémie Gadaud, Harmony Leroy, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Cancers|July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry StudyPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Leukemia|April 4, 2024
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasmsCharles Dussiau, Thibault Comont, Camille Knosp, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Pageof 4